Zacks: Brokerages Expect Nuvectra Corp (NVTR) to Post -$0.89 EPS

Equities research analysts expect Nuvectra Corp (NASDAQ:NVTR) to announce earnings of ($0.89) per share for the current quarter, Zacks Investment Research reports. Two analysts have provided estimates for Nuvectra’s earnings. The lowest EPS estimate is ($1.03) and the highest is ($0.74). Nuvectra reported earnings per share of ($0.80) during the same quarter last year, which indicates a negative year-over-year growth rate of 11.3%. The firm is scheduled to issue its next quarterly earnings results on Tuesday, March 5th.

According to Zacks, analysts expect that Nuvectra will report full year earnings of ($3.45) per share for the current year, with EPS estimates ranging from ($3.62) to ($3.27). For the next financial year, analysts anticipate that the business will report earnings of ($2.85) per share, with EPS estimates ranging from ($2.86) to ($2.83). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research analysts that cover Nuvectra.

Nuvectra (NASDAQ:NVTR) last posted its quarterly earnings results on Monday, October 29th. The company reported ($0.87) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.86) by ($0.01). The company had revenue of $14.22 million for the quarter, compared to the consensus estimate of $12.38 million. Nuvectra had a negative net margin of 87.94% and a negative return on equity of 65.86%.

A number of brokerages have weighed in on NVTR. BidaskClub lowered shares of Nuvectra from a “buy” rating to a “hold” rating in a research report on Saturday. Zacks Investment Research lowered shares of Nuvectra from a “hold” rating to a “sell” rating in a research report on Thursday. JMP Securities increased their target price on shares of Nuvectra from $18.00 to $23.00 and gave the stock a “market outperform” rating in a research report on Wednesday, August 8th. Finally, Piper Jaffray Companies reiterated a “buy” rating and set a $21.00 target price on shares of Nuvectra in a research report on Wednesday, August 8th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company’s stock. Nuvectra has an average rating of “Buy” and a consensus price target of $23.50.

In other Nuvectra news, President Joseph Paul Hanchin sold 1,250 shares of the stock in a transaction dated Monday, August 20th. The shares were sold at an average price of $20.43, for a total transaction of $25,537.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 4.60% of the stock is owned by company insiders.

A number of large investors have recently modified their holdings of NVTR. Engineers Gate Manager LP purchased a new stake in shares of Nuvectra in the second quarter worth about $437,000. Royal Bank of Canada lifted its holdings in shares of Nuvectra by 49.8% in the first quarter. Royal Bank of Canada now owns 66,046 shares of the company’s stock worth $860,000 after buying an additional 21,951 shares in the last quarter. BlackRock Inc. lifted its holdings in shares of Nuvectra by 422.6% in the second quarter. BlackRock Inc. now owns 825,252 shares of the company’s stock worth $16,943,000 after buying an additional 667,346 shares in the last quarter. Metropolitan Life Insurance Co. NY purchased a new stake in shares of Nuvectra in the second quarter worth about $105,000. Finally, Millennium Management LLC lifted its holdings in shares of Nuvectra by 3.3% in the second quarter. Millennium Management LLC now owns 481,411 shares of the company’s stock worth $9,883,000 after buying an additional 15,236 shares in the last quarter. Hedge funds and other institutional investors own 81.18% of the company’s stock.

Shares of NASDAQ:NVTR opened at $18.38 on Wednesday. The company has a debt-to-equity ratio of 0.42, a current ratio of 7.63 and a quick ratio of 7.35. The stock has a market cap of $336.33 million, a price-to-earnings ratio of -4.36 and a beta of -0.34. Nuvectra has a twelve month low of $7.60 and a twelve month high of $25.17.

Nuvectra Company Profile

Nuvectra Corporation, a neuromodulation medical device company, develops and commercializes neurostimulation technology platform for the treatment of various disorders in neuroscience and clinical markets. It operates through two segments, Nuvectra and NeuroNexus. The company offers Algovita spinal cord stimulation system that is used for the treatment of chronic pain of the trunk and limbs.

Further Reading: Stock Symbols, CUSIP and Other Stock Identifiers

Get a free copy of the Zacks research report on Nuvectra (NVTR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Nuvectra (NASDAQ:NVTR)

Receive News & Ratings for Nuvectra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvectra and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply